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Abstract
Background: The incidence of radionecrosis after radiosurgery is 5–20%. That radionecrosis after radiosurgery may
be confused with a malignant tumor is a known phenomenon and problem.
Methods: Three similarly treated patients with cAVM, 1 patient with symptomatic radionecrosis and 2 patients with
normal post-radiation MRI changes, were selected and studied in detail with magnetic resonance imaging (MRI),
magnetic resonance angiography (MRA), and magnetic resonance spectroscopy (MRS). 2 cAVM were located in
eloquent locations and were classified as Spetzler-Martin grade (SM) III such that interdisciplinary radiosurgery was
recommended; a third patient with a left frontal SM II cAVM refused surgery. 1 patient was male, and 2 were
female. The patient’s ages ranged from 38 to 62 years (median, 39 years). The nidus volume (= planning target
volume = PTV) ranged from 2.75 to 6.89 ccm (median, 6.41 ccm). The single dose was 20 Gy at the isocenter of the
PTV encompassing the 80 – 90% isodose. The median follow-up period was 20 months (range, 16 – 84 months).
Toxicities were evaluated with the Common Terminology Criteria (CTC) for adverse events version 3.0.
Results: No patient suffered a bleeding from cAVM during the study period. A complete nidus occlusion was
shown in all patients with time-resolved MRA. All patients showed radiogenic MRI changes, 1 patient showed
excessive radionecrosis. This patient was oligosymptomatic and under temporary corticoid therapy symptoms
resolved completely.
Following patterns associated with radionecrosis in the MRS studies were identified in our collective:
 2D spectroscopic imaging (2D-SI) revealed much lower concentrations of metabolites in the lesion as
compared to contralateral healthy tissue in all patients.
 Whereas regions with regular post-radiosurgery effects showed almost normal levels of Cho and a Cho/Cr
ratio < 2.0, regions with radionecrosis were characterized by increased lipid levels and a Cho/Cr ratio > 2.0
in conjunction with decreased absolute levels of all metabolites, especially of Cr and NAA.
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Conclusions: MRS is an increasingly valuable tool for the differential diagnosis of radiation reactions. Specific
patterns of MRS spectra in radionecrosis were identified; in synopsis with clinical parameters, these changes have to
be taken into account to avoid misdiagnosis.
Keywords: Radiation necrosis, Radiation injury, Magnetic resonance spectroscopy, Magnetic resonance
angiography, Radiosurgery
Background
Radiation injury or radiation necrosis is an often de-
layed, either calculated reaction or complication after
cranial radiotherapy (RT). That radionecrosis after RT
may be confused with a malignant tumor on magnetic
resonance imaging (MRI) is a known phenomenon and
problem [1]. The incidence of radiation injury after
standard fractionated external beam radiation therapy of
72 Gy is estimated to be 5% [2]. The incidence after
stereotactic radiosurgery (SRS) is reported to be 5–20%,
depending on the dose, volume and localization [3,4].
Non-invasive imaging methods, such as magnetic res-
onance spectroscopy (MRS), have been used to distin-
guish radiation injury from tumor. MRS provides
metabolic and chemical information about brain lesions.
It essentially offers in vivo chemical patterns of tissue
that reflect ongoing metabolic activity in target lesions;
e.g., cellular necrosis, gliotic changes, inflammation or
proliferation of neoplastic tissue. Single- and multivoxel
techniques may be used when performing MRS, and a
variety of metabolic markers can be measured. Choline
(Cho) levels reflect the membrane metabolism that is
associated with cellular turnover. N-acetyl-aspartate
(NAA) functions as a neuronal cell marker, while total
creatine (creatine + phosphocreatine, Cr) indicates cellu-
lar bioenergetics. Lipid and lactate peaks are present in
necrotic tissue and reflect cell membrane destruction
and anaerobic metabolism. Results from MRS may be
comparable to those from FDG-PET or SPECT [5]. Al-
though there have been some promising retrospective
studies [6-8], the true value of MRS in the differentiation
of radiation injury from neoplastic tissue remains to be
clarified [9]. Furthermore, the majority of those studies
derived their data from the radiotherapy of tumors
(gliomas or brain metastases), so that the diagnostic
utility of MRS after RT of other lesions like arteriovenous
malformations (AVMs) - as in the present study - remains
less clear.
AVMs are congenital vascular anomalies consisting of
a complex web of feeding arteries and draining veins,
linked by an abnormal capillary bed, the so-called nidus.
Clinically, AVMs are recognized mostly because of intra-
cranial hemorrhage or epilepsy, although they may re-
main silent over a long time. Because of their life-long
cumulative risk of bleeding - approximately 2% to
4% per year - therapeutic strategies are surgical resection
or complete obliteration either by radiosurgery or
endovascular intervention, and sometimes a combination
of these methods is necessary [10].
Radiosurgery can cause occlusion of the AVM nidus in
60 – 90% of cases over a 1 – 2 year period following
treatment, provided that the nidus is less than 2 – 3 cm
in diameter. MRI changes post-SRS for AVMs occur
in up to 30% of cases, depending on the treatment
volume and dose administered. Delayed symptomatic
radionecrosis occurs in up to 9% of cases, with the
majority being transient [11].
In contrast to former MRS studies, we extensively and
exclusively investigated non-tumor patients with vascu-
lar malformations (AVMs of the brain) particularly
avoiding overlaps by tumor necrosis, tumor progression
or an infiltrative zone (e.g. in gliomas). With minor
restrictions this allows for the unique opportunity to




Three similarly treated patients with AVMs (stereotactic
radiosurgery after endovascular therapy) were collected
from the total pool of AVM patients from the depart-
ment of the first author and were studied in detail with
MRI, time-resolved magnetic resonance angiography
(MRA) [12], and MRS. This included one patient with
symptomatic radionecrosis and two patients with normal
post-radiation MRI changes.
The patient with radionecrosis received additional MRI
and MRS studies to exclude a secondary malignancy.
2 AVMs were located in an eloquent location and
were classified as Spetzler-Martin grade (SM) III with a
markedly increased risk in case of surgery, one patient
with a left frontal SM II AVM refused surgery. The
patients were therefore alternatively treated with radio-
surgery, in all cases after multiple (2 – 3) partial
embolizations.
Complete nidus occlusion (17 months after radiosur-
gery) was shown by time-resolved MRA and confirmed
using conventional digital subtraction angiograpy (DSA)
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in one patient. In the other two patients (16 months re-
spectively 7 years after irradiation) nidus occlusion could
also be demonstrated by time-resolved MRA as an alter-
native to conventional DSA, which was refused in both
cases. In 2 patients the diagnosis of the AVM was an in-
cidental finding, the other patient reported dizziness and
headache, which could not definitely be related to the
AVM. No patient has suffered an AVM bleeding until
now. The patients and AVM characteristics are summa-
rized in Table 1.
Radiosurgical treatment
All three patients with AVM were treated with SRS dur-
ing December 2004 and April 2009 using the the
NovalisW radiosurgical system (BrainLABW, Feldkirchen,
Germany) at the Department of Radiosurgery and
Stereotactic Radiotherapy, Mediclin Robert Janker Clinic
Bonn, Germany. The used NovalisW system consists of a
6 MV LINAC (VarianW Medical Systems, Palo Alto, CA,
USA) equipped with a micro-multi-leaf-collimator with
a leaf thickness of 3 mm and a robotic couch (VarianW
Medical Systems, Palo Alto, CA, USA). After sharp fix-
ation in the stereotactic frame (BrainLABW, Feldkirchen,
Germany) patients underwent first stereotactic angiog-
raphy and then a planning computed tomogram (CT)
using the same localizer. Scanning was performed with
1–3 mm slice thickness without gap for treatment plan-
ning using a CT-based 3D treatment planning system.
After stereotactic registration and image fusion with a
MRI data set that was obtained the day before, the nidus
first was determined on stereotactic angiograms in a
strictly a.p. and lateral view. The nidus was defined as
the planning target volume (PTV). Critical structures
were drawn slice by slice using fused high spatial-
resolution T1- and T2-weighted MRI data. In a second
step, the PTV was modified based on the results of MRI
and then re-evaluated with the angiograms. 3-D dose
distribution was calculated by BrainSCAN 5.3x until
2008, since 2009 we use iPlanNet/iPlanRT 4.0x; (both
BrainLABW, Feldkirchen, Germany). Conformal treat-
ment plans were designed for all cases using a planning
algorithm that involved setting dose constraints to
minimize irradiation delivered to critical structures such
as optic pathways and the brain stem. 9 conformal non-
coplanar static beams in all 3 patients were used. All tar-
gets were treated with a single isocenter. The single dose
was 20 Gy at the isocenter of the PTV encompassing the
80–90% isodose. Maximum target dose did not exceed
107% and there was no significant radiation dose applied
to the organs at risk (OAR). All delivery parameters
were according to the guidelines of the Radiation
Therapy Oncology Group (RTOG) for stereotactic radio-
therapy including a conformity index (CI) between 1.0
and 2.0.
Radiosurgery was well tolerated without acute toxic-
ities within the first 6 months in all cases. Toxicities
were evaluated with the Common Terminology Criteria
(CTC) for Adverse Events version 3.0. Radionecrosis was
defined in accordance with Blonigen et al. as (1) any pa-
tient requiring steroid therapy with MRI changes, (2)
characteristic MRI changes that persisted on two con-
secutive scans, (3) MRS findings consistent with necrosis
or (4) histologic evidence of necrosis [13].
Follow-up evaluation
After SRS, follow-up was performed after 6 months, 12
months, and thereafter at intervals of 12 months. Regu-
lar follow-up studies included clinical examination, brain
MRI, and a single DSA examination 1.5 - 2 years after
radiosurgery.
MRS acquisition and evaluation
1H-MRS was performed on 3.0 Tesla whole-body MR
systems (Achieva 3.0 TX and Ingenia 3.0 T, Philips
Healthcare) using a birdcage quadrature head coil for
signal transmission and reception. 2D spectroscopic im-
aging (2D-SI) was acquired with TR/TE 1750/140 ms at
the level of the AVM nidus as an axial slice with 2 cm
thickness and 162 matrix elements reconstructed to
20x20 over a field of view (FOV) of 160 mm, thus yield-
ing an in-plane voxel size of 8 mm. Water suppression
was achieved by Gaussian excitation pre-pulses, and sig-
nal contamination from skull lipids was reduced by
restricting spin excitation and refocusing to a PRESS-
localized [14] volume of interest (VOI) of 100 x 100 mm
centered within the brain. In addition, water-suppressed
single-voxel (SV) MRS in a small VOI encompassing the
contrast-enhancing part of the lesion was performed
Table 1 Summary of patients’ data with special respect to Spetzler-Martin grade (SM), AVM size (maximal diameter in
cm), Localization, Eloquence (+/−), Presentation prior to radiosurgery, Venous drainage (D= deep, S= superficial),
Rupture before treatment (+/−) and additional treatment modality (E=Embolization)




1 64 F None - 3 2.4 Left frontal operculum + S + D 3 x E
2 39 M Headache - 2 2.7 F2 and Left frontal white matter + S 2 x E
3 38 F None - 3 3.0 Fronto-lateral left - S+D 3 x E
M=male, F=female.
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with TR 2000 ms and TE140 ms. 2D-SI and SV spectra
were sampled with 1024 data points at 2 kHz bandwidth,
corresponding to a non-interpolated frequency reso-
lution of 2 Hz/pt, and SV was averaged over 128 signal
excitations. In all 3 AVM cases, short echo-time SV with
TE 30 ms and 64 signal averages was additionally ac-
complished to analyse lipid signal components in more
detail and to assess spin-coupled metabolites like myo-
inositol and glutamate/glutamine. Absolute quantifica-
tion of metabolite concentrations from the SV spectra
was achieved as described in [15,16]. In brief, the NAA
signal was referenced to the signal of internal tissue
water within the VOI obtained from unsuppressed MRS
with TR/TE 3500/80 ms, and metabolite levels were fur-
ther corrected for partial cerebrospinal fluid (CSF) vol-
ume within the VOI. Total measurement time for all
2D-SI and SV acquisitions was less than 20 min.
2D-SI and SV spectra were time-domain quantified apply-
ing the AMARES algorithm of the MRUI software package
[17,18] after preprocessing with matched Lorentz-Gauss
filtering. From the 2D-SI data, signal ratios of Cho/Cr,
Cho/NAA, and NAA/Cr were determined for selected
spectra within the lesion area (averaged over all con-
tiguous 2D-SI voxels comprising more than 50% of
contrast enhancing tissue) and were compared to those
for corresponding voxels in the contra-lateral hemisphere,
as well as intensity ratios of the respective metabolite in
the lesion voxels relative to the contra-lateral voxels.
Absolute levels of Cho, Cr, and NAA obtained from
the SV measurements in the radiogenic lesion as well
as the metabolite ratios were compared to normal
values for the respective cerebral region [19].
Statistical analysis
Statistical analysis was performed using Excel (Microsoft,
Seattle, WA, USA) software.
Results
Radiogenic changes were observed in all patients in
follow-up MRI. In one patient, radionecrosis with pro-
nounced blood–brain-barrier disruption and a moder-
ately space-occupying edema was found; this patient was
oligosymptomatic and symptoms resolved completely
after temporary high-dose cortisone therapy.
Illustrative case presentation with repeated MRS
(Patient #1 Tables 1, 2, 3).
An incidental left frontal arterio-venous-malformation
(AVM) was found in a 62 year old female who presented
with unrelated vision impairment. The AVM was related
to the internal capsule and Broca area and showed no
signs of former bleeding. After DSA and WADA testing
it was classified as Spetzler Martin grade III. Microsurgi-
cal resection was considered too riskful; therefore it was
treated with 3 partial embolizations followed by radio-
surgery. All delivery parameters were according to the
guidelines of the RTOG for stereotactic radiotherapy in-
cluding a CI of 1.68 (Figure 1). 16 months after radiosur-
gery she developed aphasia. Under steroid therapy, a
complete remission was achieved. Follow up MRI in-
cluding temporally-resolved MR angiography revealed a
complete elimination of the nidus, but at the same time
showed a ring enhancement and a marked perifocal
edema (Figure 2). Additional MRS in the enhancing area
measured a high ratio of Cho to Cr (> 2.0) suspicious for
malignancy, although absolute concentration of Cho was
not increased (Figure 3). In MRI control after 4 and 20
months, ring enhancement was unchanged and the
perifocal edema showed slight regression (Figure 4).
MRS revealed a stable metabolic pattern over a time
course of 4 months with persistent high Cho/Cr, ex-
tremely low NAA concentration < 1 mmol/L, and
strongly decreased Cr levels < 3 mmol/L. Taking into ac-
count that our patient requires steroid therapy, that the
MRI changes were stable on more than two consecutive
scans, were only slightly regredient over a 20 months
period and did not reverse completely, and that the re-
peated MRS findings finally were consistent with necro-
sis, we scored this case as radionecrosis.
MRS results
Table 3 summarizes for each MRS examination of the
patients the relative and absolute concentrations of Cho,
Cr, and NAA obtained from SV-MRS in the lesion, as
well as the ratios of the metabolite levels within the
AVM lesion measured by 2D-SI (averaged over all spec-
tra from the contrast-enhancing area) relative to those
of corresponding voxels in the unaffected contra-lateral
hemisphere (side comparison). Further, metabolite ratios
determined for the unaffected contra-lateral voxels and
Table 2 Summary of SRS treatment data, PTV=planning target volume, Dose = single treatment dose in Gy prescribed
to the isodose line covering 80 – 90% of the PTV, B=conformal non-coplanar static beams, CTC=Common Terminology
Criteria for Adverse Events, version 3.0
No Nidus=PTV (ccm) Dose (Gy) Technique Nidus occlusion Radionecrosis Adverse events (CTC grade)
1 2.75 20 9 B + + transient Broca aphasia 1°
2 6.89 20 9 B + - none
3 6.41 20 9 B + - none
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normal metabolite concentrations [19] in the respective
cerebral region are included for comparison. The choline /
creatine ratio in the lesion of the 2 patients without
radionecrosis remained below 1.7 and was considerably
smaller than in AVM patient #1 with radionecrosis, and in
the 2D-SI side comparison the choline level in the lesion
was less than 65% of the contra-lateral value while in the
patient with radionecrosis the relative Cho level reached
about 80-85%. Nevertheless, all cases revealed consider-
ably lower concentrations of metabolites in the lesion site.
In the 2D-SI and SV spectra from the AVM lesion of the
patient with radionecrosis a high peak from (phospho)
lipids was observed even at the long TE 140 ms (Figure 3),
whereas the lipid signal was not or only slightly increased
in the two patients with normal post-interventional state
(Figure 5).
Discussion
Our study contributes to the understanding of radionecrosis
in radiosurgically treated AVM. Radionecrosis, being a
Table 3 Summary of MRS data obtained from single-voxel (SV) acquisitions and from 2D spectroscopic imaging (2D-SI)
in the three patients
No. Single-voxel MRS (SV) in AVM lesion 2D-SI
contra-lateral
Cho/Cr NAA/Cr [Cho] [Cr] [NAA] Cho Cr NAA Cho/Cr NAA/Cr
metabolite ratios (mmol/L) (mmol/L) (mmol/L) signal ratios lesion/contra-lateral metabolite ratios
1 a 2.08 0.39 1.59 2.86 0.80 0.84 0.32 0.09 1.23 2.15
1 b 2.67 0.46 1.41 1.98 0.65 0.81 0.41 0.22 1.02 1.97
2 1.38 1.05 1.68 5.02 3.78 0.64 0.62 0.34 1.27 2.27
3 1.69 1.23 2.00 4.49 4.01 0.46 0.28 0.26 0.98 1.74
Normal values (from [19])
Mean 1.11 2.81 2.07 6.99 14.51
SD 0.16 0.29 0.40 0.85 1.42
In the first column, 1a and 1b denote the initial and the second (4 months later) therapy follow-up MRI/MRS examination of patient #1, respectively. In the next
columns, Cho/Cr and NAA/Cr represent metabolic ratios determined from the SV spectra at TE 140 ms, and the absolute concentrations of choline, creatine, and
NAA as derived from the SV acquisitions in the lesion are listed. The 2D-SI results comprise the ratios of the signal intensity of the respective metabolite within
the AVM lesion relative to that in the corresponding voxels in the unaffected contra-lateral hemisphere, and in the last two columns the metabolite ratios Cho/Cr
and NAA/Cr measured in the contra-lateral voxels are shown. Below the patient results, normal values for relative and absolute metabolite levels in frontal/parietal
white matter, taken from [19] are given for comparison.
a b c
d e f
Figure 1 Incidental left frontal cerebral arteriovenous malformation in a 65 year-old woman after 3 partial embolizations (patient #1).
Maximum intensity projections of pre-operative dynamic 4D-MR angiography (a: frontal view, b: saggital view), treatment planning (c: fused DSA
and planning target volume (PTV), d-f: fused CT with PTV and isodose lines).








Figure 2 Same patient as Figure 1. Pre- and post-treatment MRI (FLAIR: a,c; contrast-enhanced MRI: b,d), e-h: fused post-treatment MRI). Red












Figure 3 Same patient as Figure 1. MR spectroscopy (TE 140 ms) in first post-treatment examination. a: Display of 2D-SI grid (red) over FOV of
160 mm, PRESS-localized VOI of 100 mm (green frame), spectra selection grid (yellow) on T2-weighted MRI (top), and of 34 selected 2D-SI spectra
(below) from the lesion area arranged in a pattern corresponding to the yellow grid. b: SV-spectrum from a 9 mL-VOI (red frame in Figure 2c,d) in
AVM lesion shows strongly reduced Cr, barely visible NAA, and a high lipid peak. c: 2D-SI spectrum from healthy tissue contralateral (blue-framed
grid element in a) to the AVM.
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calculated reaction in tumor radiosurgery, has to be avoided
strictly in AVM radiosurgery. In this situation the goal is to
obliterate the AVM blood vessels, because radionecrosis of
brain may involve excessive undesirable side effects includ-
ing perifocal edema and mass effect. Our data may be a
valuable contribution to the better understanding of radio-
genic changes after radiosurgery in MRS studies and differ-
entiate them from primary or secondary brain malignancies.
Changes after radiotherapy may be extremely complex.
Irradiated tissues may undergo several coexisting pro-
cesses, including progressive cellular necrosis and gliosis,
inflammatory changes, and reactive glial cell prolifera-
tion. In malignant lesions, coexisting radiation-induced
changes and residual tumor have also been observed. As
a consequence, the interpretation of MRS and MRI may
also be complex. For instance, tumor recurrence after
high dose RT likely additionally contains both tumor
and necrosis components. Furthermore, in a heteroge-
neous lesion of both tumor and necrosis after RT, either
single-voxel or multi-voxel MRS may not capture the
tumor cluster due to partial volume averaging [8].
In our study, for the first time we were able to extensively
study radiogenic changes including those in MRS in
radionecrosis in non-tumor patients; therefore, influencing
factors like tumor progression or the presence of an in-
filtrative zone as they are typically observed in gliomas,
are eliminated in our patients. This results in the unique
opportunity to study MRS changes in vivo that are likely
a result of almost pure radionecrosis in non-tumorous
brain tissue, especially since there was no former bleeding
with potential brain damage in any of the cases.
We identified the following metabolic patterns associ-
ated with radiation necrosis:
 In regions with coexisting cellular necrosis and reactive
mechanisms (normal post interventional state), no
increase in Cho and a Cho/Cr ratio < 2.0 was found.
 In regions with predominantly cellular necrosis
(radionecrosis), increased lipid levels, but unchanged
or slightly decreased levels of Cho and extremely
reduced NAA and Cr levels were found with a
markedly increased Cho/Cr ratio > 2.0.
The embolization material was analyzed separately
using MRS in vitro. Because of the lack of material-
specific lipid peaks at the in-vivo MRS examinations,
we could unambiguously identify radiogenically induced
phospholipid peaks.
In this study, MRS did perform as well as previously
reported for differentiating radiation injury from ma-
lignant tumor [6-8]. However, prior publications were
primarily focused on observations in glioma patients
after fractionated RT or on brain metastases treated
with high doses of single fraction radiosurgery [6-8].
ba c
d e f
Figure 4 Same patient as Figure 1. Additional follow-up post-treatment examinations reveal constant hyperintensities in FLAIR (a-c)
and contrast-enhanced MRI (d-f [f = axial MPR]) six weeks (a,d), three more months (b,e), and 20 months (c,f) after initial post-treatment MRI as
shown in Figure 2 indicating non-malignant disease.
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In the literature, Cho concentration and the Cho/Cr ratio
are considered to be the most useful markers for the differ-
entiation of neoplasms from radiation necrosis in MRS.
Spectra with distinctly elevated absolute Cho levels and/or
Cho/Cr > 2.0 are considered suggestive of a malignant
tumor [8]. Our cases demonstrate the importance of careful
consideration of the absolute values of the individual me-
tabolites, especially the Cr level, because a necrosis-induced
strong reduction in Cr may likewise lead to large Cho/Cr
ratios. Furthermore, it has to be kept in mind, that the
known cut-off value for Cho/Cr is appropriate for most
parts of the frontal and parietal brain, but will be too high
for lesions in cerebral regions with naturally low Cho
concentrations, for instance in the occipital lobe [20].
MRS has a published sensitivity of 81% and a specifity of
71% for differentiation between recurrent tumor and radi-
ation necrosis [21]. Results from MRS may be comparable
to those from FDG-PET or SPECT. [18F]FDG-PET has a
sensitivity of 75% and a specificity of 81% for the detection
of recurrent tumor versus radiation necrosis [22]. More-
over, in patients after stereotactic radiotherapy for brain
metastasis, co-registration of [18F] FDG-PET images with
MRI yields an improvement of the sensitivity for the detec-
tion of recurrent tumor from 65 to 86% [23]. In the recent
years [11C] MET-PET has shown to be successfull in
differention between recurrent tumor and radiation necro-
sis [24,25], similar results have been obtained with other
tracers [26,27]. Foroughi et al. reported some cases of AVM
after radiosurgery with false positive results suggestive for
malignancy and recommended caution when attempting to
differentiate radionecrosis from neoplasia using SPECT
scans [11].
Finally, amide proton transfer imaging in 7 Tesla MRI









Figure 5 MRS in AVM patient (#2) with normal post-interventional state. Radiogenic changes after treatment are seen as hyperintensities in
axial FLAIR (a) and sagittal contrast-enhanced MRI (b). c: SV-spectrum from 6 mL-VOI (yellow frame in a, b) in AVM lesion reveals a moderately
increased Cho/Cr ratio of 1.38 and smaller signal from lipids.
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first results concerning radionecrosis after AVM radio-
surgery were recently published by Gerigk et al. in 2012
[28], but the applied technology and the required MR
equipment are highly challenging and available only to
very few clinical centers, and its usefulness has still to be
evaluated in larger patient samples.
In our opinion, imaging techniques like MRS and
PET/SPECT or APT imaging cannot alone prove a
radionecrosis, they should not be regarded as competing
but as complementary methods, and they can only be a
supplement to conventional imaging and have always to
be evaluated in context with the clinic.
In clinically and by MRI imaging doubtful cases, MRS in
our opinion provides useful information and just helps in
some cases to avoid a possibly unnecessary invasive
procedure such as re-operation or biopsy. With hints for
radionecrosis the duration of high-dose antiedematous
dexamethasone therapy maybe will be shorter, because be-
side strong MRI changes most patients with radionecrosis
are a- or oligosymptomatic and a long-time cortisone
therapy is not necessary. In some special cases instead of
high-dose cortisone a more specific therapy with the
monoclonal vascular endothelial growth factor (VEGF)
antibody bevacizumab may be useful. In 2011 for the first
time at a larger scale, Levin et al. have described a therapy
effect of bevacizumab in radiation necrosis confirming the
relative new theory that blocking VEGF at an early stage
with bevacizumab could be an option to reduce the devel-
opment of radiation necrosis by decreasing the vascular
permeability [29].
Limitations
Due to the relatively large required voxel size for SV-
MRS, partial volume averaging over tissue with a mix-
ture of coexisting processes like cellular necrosis and cell
proliferation represents significant obstacles in the diag-
nostic accuracy of MRS. Spectroscopic imaging allows
better spatial resolution, but at the cost of reduced
signal-to-noise, longer measurement time and increased
artifact sensitivity.
Our small sample size does not allow for generalization
of our results and must be confirmed by further studies
with larger sample size. However, the unique opportunity
to obtain spectroscopic data of a lesion, which is imaging-
wise suspicious for malignancy after radiation therapy of a
benign lesion and the detection of the importance of not
concentrating on the metabolite ratios alone, but to care-
fully take the absolute concentrations into account, are
important findings that need to be carefully regarded in
interpretation of spectroscopic results.
Conclusions
We were able to extensively examine radiogenic changes
(radionecrosis) by means of MR spectroscopy in AVM
patients treated with radiosurgery. In contrast to other
studies, for the first time we systematically investigated
non-tumorous lesions avoiding overlays by tumor necro-
sis; this enabled us to study (with minor restrictions)
radionecrosis after radiosurgery in its pure form and
specific patterns of MRS spectra regarding radionecrosis
were identified; however, the results can be misleading
and must be interpreted with caution in context with
the clinic to avoid misdiagnosis. MRS is a supplement to
the conventional imaging, and no therapy decision
should be based solely on MRS data.
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